Control of allergic rhinitis in four latin american countries: Rinola study.
Latin America
allergic rhinitis
control
score
validated tools
Journal
Frontiers in allergy
ISSN: 2673-6101
Titre abrégé: Front Allergy
Pays: Switzerland
ID NLM: 9918227355906676
Informations de publication
Date de publication:
2022
2022
Historique:
received:
28
06
2022
accepted:
01
08
2022
entrez:
12
9
2022
pubmed:
13
9
2022
medline:
13
9
2022
Statut:
epublish
Résumé
Allergic rhinitis (AR) affects up to 40% of the general population, there are large-scale multicenter studies that have described its characteristics and few studies have focused on studying patients with AR in Latin America (LA). A cross-sectional, descriptive, multicenter study was carried out in four LA countries (Colombia, Argentina, Cuba and Peru). Patients diagnosed with AR between November 2017 and June 2020 were included. Sociodemographic and clinical data, sensitization profile and current treatment were collected in the Electronic Data Collection (BDClinic). Patients also filled out this questionnaires: Rhinitis Control Assessment Test (RCAT), Reflexive Total Nasal Symptom Score (rTNSS), Modified ARIA Criteria for AR Severity (mARIA) and ESPRINT-15. Risk of bias was examined by applying the STROBE checklist. The study included 412 patients. Median age was 25 years (15-39). Two hundred and twenty four (54.3%) were women. Nasal obstruction was present in 303 (73.5%). Three hundred and thirty four (81%) had a persistent AR. One hundred and twenty one (31.3%) had associated asthma. The most frequently positive skin tests were: These findings confirm that most of patients with AR in LA have a persistent disease with a negative impact on quality of life. Dust mites are the main sensitizers. These findings will allow to know the true impact of AR and can lead to a better disease management.
Sections du résumé
Background
UNASSIGNED
Allergic rhinitis (AR) affects up to 40% of the general population, there are large-scale multicenter studies that have described its characteristics and few studies have focused on studying patients with AR in Latin America (LA).
Methodology
UNASSIGNED
A cross-sectional, descriptive, multicenter study was carried out in four LA countries (Colombia, Argentina, Cuba and Peru). Patients diagnosed with AR between November 2017 and June 2020 were included. Sociodemographic and clinical data, sensitization profile and current treatment were collected in the Electronic Data Collection (BDClinic). Patients also filled out this questionnaires: Rhinitis Control Assessment Test (RCAT), Reflexive Total Nasal Symptom Score (rTNSS), Modified ARIA Criteria for AR Severity (mARIA) and ESPRINT-15. Risk of bias was examined by applying the STROBE checklist.
Results
UNASSIGNED
The study included 412 patients. Median age was 25 years (15-39). Two hundred and twenty four (54.3%) were women. Nasal obstruction was present in 303 (73.5%). Three hundred and thirty four (81%) had a persistent AR. One hundred and twenty one (31.3%) had associated asthma. The most frequently positive skin tests were:
Conclusion
UNASSIGNED
These findings confirm that most of patients with AR in LA have a persistent disease with a negative impact on quality of life. Dust mites are the main sensitizers. These findings will allow to know the true impact of AR and can lead to a better disease management.
Identifiants
pubmed: 36092279
doi: 10.3389/falgy.2022.980515
pmc: PMC9448887
doi:
Types de publication
Journal Article
Langues
eng
Pagination
980515Informations de copyright
© 2022 Silva, De Barayazarra, Valero, Garcia, Uriarte, Peñaranda, Chapman, Garcia, Ocampo, Valencia, Moreno, Corelli, Lopez, Ramirez, Perez, Jares and Serrano.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Allergy Clin Immunol. 2007 Aug;120(2):359-65
pubmed: 17531304
Int Arch Allergy Immunol. 2010;151(3):255-61
pubmed: 19786806
J Investig Allergol Clin Immunol. 2013;23(1):14-9
pubmed: 23653969
Allergol Select. 2019 Dec 30;3(1):22-50
pubmed: 32176226
J Allergy Clin Immunol. 2004 Apr;113(4):663-8
pubmed: 15100670
J Allergy Clin Immunol. 2017 Oct;140(4):950-958
pubmed: 28602936
J Investig Allergol Clin Immunol. 2014;24(1):23-8
pubmed: 24765877
Allergy Asthma Proc. 2010 May-Jun;31 Suppl 1:S9-27
pubmed: 20557683
Allergy Asthma Proc. 2008 Nov-Dec;29(6):600-8
pubmed: 19173786
Treat Respir Med. 2005;4(6):439-46
pubmed: 16336028
J Allergy Clin Immunol. 2001 Nov;108(5 Suppl):S147-334
pubmed: 11707753
Int Arch Allergy Immunol. 2017;172(4):224-235
pubmed: 28456795
J Investig Allergol Clin Immunol. 2020;30(3):175-181
pubmed: 31135377
J Med Econ. 2011;14(3):305-14
pubmed: 21488807
Allergy. 2009 Jul;64(7):1083-92
pubmed: 19210346
World Allergy Organ J. 2008 Sep;1(9):138-44
pubmed: 23282577
J Investig Allergol Clin Immunol. 2009;19(3):167-72
pubmed: 19610258
Arch Bronconeumol. 2005 Oct;41(10):569-78
pubmed: 16266671
Postgrad Med. 2009 Jan;121(1):122-31
pubmed: 19179820
Ophthalmic Epidemiol. 2005 Aug;12(4):233-42
pubmed: 16033744
Allergy. 2007 Apr;62(4):367-72
pubmed: 17362246
Clin Transl Allergy. 2017 Jun 1;7:17
pubmed: 28572918
Biomedica. 2016 Sep 01;36(3):463-474
pubmed: 27869395
J Allergy Clin Immunol. 2011 Jan;127(1):57-63, 63.e1-3
pubmed: 21211641
J Allergy Clin Immunol Pract. 2019 Jan;7(1):272-278
pubmed: 29886146
Respir Med. 2013 Jan;107(1):23-9
pubmed: 23146556
Clin Transl Allergy. 2013 Feb 18;3(1):7
pubmed: 23419058
Value Health. 2007 Nov-Dec;10(6):466-77
pubmed: 17970929
J Allergy Clin Immunol. 2013 Feb;131(2):379-86
pubmed: 23219170
J Allergy Clin Immunol. 2010 Sep;126(3):466-76
pubmed: 20816182
Allergol Immunopathol (Madr). 2017 Jan - Feb;45(1):11-17
pubmed: 27914830
J Allergy Clin Immunol Pract. 2018 Jul - Aug;6(4):1274-1286.e9
pubmed: 29017832
PLoS One. 2020 Feb 13;15(2):e0228533
pubmed: 32053609
Am J Rhinol Allergy. 2017 Jan 9;31(1):19-28
pubmed: 28234147